ASX Share rice
Mon 17 May 2021 - 10:35:am (Sydney)

TAM Share Price

TANAMI GOLD NLTAMMaterials

TAM Company Information

Name:

Tanami Gold NL

Sector:

Basic Materials

Industry:

Gold

GIC Industry:

Metals & Mining

GIC Sub Industry:

Gold

Address:

39 Mends Street South Perth WA Australia 6151

Phone:

61 8 6373 5130

Chief Financial Officer:

Mr. Daniel K. Broughton

Company Sec.:

Ms. Pauline Anne Collinson

Company Overview:

Tanami Gold NL, together with its subsidiaries, engages in the exploration and evaluation of gold properties in Australia. Its flagship project is the Central Tanami Project located in the Tanami Desert in the Northern Territory. The company was incorporated in 1968 and is based in South Perth, Australia.

TAM Share Price Information

Shares Issued:

1.18B

Market Capitalisation:

$94.01M

Earnings per Share:

$0.015

Return On Assets (TTM):

$-0.01

Return On Equity (TTM):

$0

QuarterlyEarnings Growth(YOY):

1.941

TAM CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$893K

Change To Liabilities:

$-20,000

Total Cashflow From Investing Activities:

$0.93M

Net Income:

$193K

Total Cash From Operating Activities:

$-333,000

Depreciation:

$5K

Other Cashflow From Investing Activities:

$38K

Change To Account Receivables:

$36K

Capital Expenditures:

$0

TAM Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-316,000

Net Income:

$193K

Operating Income:

$-816,000

Other Operating Expenses:

$-38,000

Income Tax Expense:

$-509,000

TAM Balance Sheet

Balance Sheet Date:

2020-06-30

Total Liabilities:

$1.79M

Total Stockholder Equity:

$49.29M

Total Assets:

$51.08M

Common Stock:

$317.64M

Retained Earnings:

$-270,650,000

Other Liabilities:

$1.66M

Other Assets:

$2.51M

Cash:

$28.95M

Total Current Liabilities:

$81K

Property - Plant & Equipment:

$12.93M

Net Tangible Assets:

$49.29M

Total Current Assets:

$35.64M

Net Receivables:

$63K

Short-Term Investments:

$15.44M

Accounts Payable:

$68K

Short-Term Investments:

$15.44

Non Current Liabilities Total:

$1.71M

TAM Share Price History

TAM News

12 May, 2021
LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the release of preliminary data relating to the use of a novel cell therapy approach in controlling human immunodeficiency virus (HIV) in humans. Dr. Serhat Gumrukçu, co-founder and inventor of Enochian BioSciences and Director of the Seraph Research Institute (SRI), presented the findings at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Presentation can be found at https://www.enochianbio.com/about-us/collaborations/ A 54-year-old man, diagnosed with HIV in 1986, had persistent HIV detected in his blood, despite antiretroviral therapy. With approval from an Institutional Review Board, this single patient was treated with a novel cellular therapy of natural killer (NK) and gamma delta T-cells (GDT) – a small subset of immune cells that can be infected with HIV but could also be a key factor in controlling the virus. The NK and GDT cells were collected from a person who does not have HIV. Because the patient stopped antiviral treatment and received some supportive medication before the cellular therapy, the level of HIV initially increased, as expected. However, HIV levels began to decline after approximately three weeks, and after 100 days dropped below the detection level of routinely used blood tests (20 copies/ml). HIV levels in the patient’s blood have remained at or below detection for an additional 255 days, all while the patient has not been taking antiviral medication. This innovative cell therapy could be a potential strategy to achieve a “functional cure” for HIV. This could potentially allow persons living with HIV to stop antiviral treatment for extended periods of time. Dr. Gumrukçu and SRI are currently pursuing a regulatory pathway with the FDA to study the approach in more patients. Enochian BioSciences holds the exclusive license for the proprietary technology. Dr. Mark Dybul, a prominent global HIV expert and Executive Vice Chair of Enochian BioSciences said, “As an HIV researcher, clinician and former leader of large, global HIV treatment programs, I am excited by these results. Although antiviral treatment is very effective, it is expensive and some patients cannot, or do not want to receive it. This, combined with the fact that access to antiviral treatments is limited, creates a significant unmet medical need. While the findings presented are preliminary and in one person with HIV, I’m hopeful that with further testing in larger patient populations, SRI’s novel cell therapy approach could one day be an alternative HIV treatment to many.” About Enochian BioSciences, Inc.Enochian BioSciences, Inc. is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. The company’s gene-modified cell therapy platform can be applied to multiple indications, including HIV/AIDS and Oncology. For more information, please visit www.enochianbio.com About Seraph Research Institute (SRI)Seraph Research Institute is a Los Angeles-based non-profit research institution, which runs basic science, translational and clinical research in pursuit of cures and effective treatments for chronic viral infections, cancers, and genetic disorders. For more information, please visit Seraphinstitute.org Forward-Looking StatementsStatements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences’ most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The findings in this press release are preliminary and based on one person. There is no assurance the findings will result in an effective alternative treatment for HIV. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. CONTACT: Contact: ir@enochianbio.com
(NASDAQ: ENOB) – A novel approach to HIV cell therapy developed by Dr. Serhat Gumrukçu (Dr. Serhat), Director of the Seraph Research Institute (SRI), and his team was presented yesterday as a new approach to treating HIV in humans. The research findings and developments were presented at the 2021 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) to thousands of industry attendees.